MKI67 and neoplasm: Similarly, the frequency of Ki67+ tumor cells was significantly decreased in vevorisertib (9.3 ± 1.1, p = 0.0293) and the vevorisertib + sorafenib group (6.0 ± 0.8, p = 0.0007) groups compared to the control group (43.7 ± 11.3), Figure 3c,d.